BBIO.US BridgeBio Pharma Inc

Healthcare Biotechnology USA Stocks
78.30 USD
Close of Nov 14, 2026
62.50 93.42
Market cap
USD 15.3B
P/E
-
P/B
123.68x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BBIO.US undervalued?

Graham number

The Graham number of BridgeBio Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BridgeBio Pharma Inc fundamental analysis

No fundamental analysis for BridgeBio Pharma Inc yet.

BridgeBio Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BridgeBio Pharma Inc

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NU…

Full company profile